FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043186322> ?p ?o ?g. }

• W2043186322 endingPage "914" @default.
• W2043186322 startingPage "908" @default.
• W2043186322 abstract "Background Mitogen-inducible gene-6 (Mig-6) is an immediate early response gene that negatively regulates signaling. EGFR overexpression and activating mutations in MAPK signaling effectors are common events in papillary thyroid cancer (PTC). The purpose of this study was to determine if Mig-6 expression is associated with EGFR expression or surgical outcomes in PTC. Methods We determined Mig-6 transcript levels from a microarray in 19 patients with PTC who underwent thyroidectomy. We established a maximally selected cutoff to discriminate Kaplan-Meier survival estimates. For cross-validation, we performed quantitative RT-PCR on resected well-differentiated PTC from an additional 106 patients. Results Mig-6 and EGFR mRNA levels correlated directly (P < .0001). Mig-6 expression above the cutoff of 1.10 (2^-dCt[Mig6-GUS]) was associated with greater survival (P = .008). When this cutoff was applied in the cross-validation, high Mig-6 expression was associated with longer survival (P = .03) and disease-free survival (P = .07). Furthermore, high Mig-6 expression was independently predictive of greater disease-free survival in BRAFV600E-positive PTC. Conclusion High Mig-6 expression in PTC is associated with favorable outcomes. Mig-6 is a novel tumor suppressor that may be a candidate for targeted cancer therapeutics in patients with PTC refractory to conventional therapy. Mitogen-inducible gene-6 (Mig-6) is an immediate early response gene that negatively regulates signaling. EGFR overexpression and activating mutations in MAPK signaling effectors are common events in papillary thyroid cancer (PTC). The purpose of this study was to determine if Mig-6 expression is associated with EGFR expression or surgical outcomes in PTC. We determined Mig-6 transcript levels from a microarray in 19 patients with PTC who underwent thyroidectomy. We established a maximally selected cutoff to discriminate Kaplan-Meier survival estimates. For cross-validation, we performed quantitative RT-PCR on resected well-differentiated PTC from an additional 106 patients. Mig-6 and EGFR mRNA levels correlated directly (P < .0001). Mig-6 expression above the cutoff of 1.10 (2^-dCt[Mig6-GUS]) was associated with greater survival (P = .008). When this cutoff was applied in the cross-validation, high Mig-6 expression was associated with longer survival (P = .03) and disease-free survival (P = .07). Furthermore, high Mig-6 expression was independently predictive of greater disease-free survival in BRAFV600E-positive PTC. High Mig-6 expression in PTC is associated with favorable outcomes. Mig-6 is a novel tumor suppressor that may be a candidate for targeted cancer therapeutics in patients with PTC refractory to conventional therapy." @default.
• W2043186322 created "2016-06-24" @default.
• W2043186322 creator A5003360187 @default.
• W2043186322 creator A5006600520 @default.
• W2043186322 creator A5018065633 @default.
• W2043186322 creator A5018703548 @default.
• W2043186322 creator A5019885091 @default.
• W2043186322 creator A5040025890 @default.
• W2043186322 creator A5043079481 @default.
• W2043186322 creator A5056250241 @default.
• W2043186322 creator A5066779282 @default.
• W2043186322 creator A5076916905 @default.
• W2043186322 creator A5078377958 @default.
• W2043186322 creator A5080440906 @default.
• W2043186322 creator A5089773064 @default.
• W2043186322 date "2008-12-01" @default.
• W2043186322 modified "2023-09-24" @default.
• W2043186322 title "Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAFV600E positive papillary thyroid cancers" @default.
• W2043186322 cites W1979109241 @default.
• W2043186322 cites W2017177890 @default.
• W2043186322 cites W2023325202 @default.
• W2043186322 cites W2030588978 @default.
• W2043186322 cites W2033869679 @default.
• W2043186322 cites W2042816516 @default.
• W2043186322 cites W2045562658 @default.
• W2043186322 cites W2055750013 @default.
• W2043186322 cites W2056192215 @default.
• W2043186322 cites W2060671481 @default.
• W2043186322 cites W2063524499 @default.
• W2043186322 cites W2064406595 @default.
• W2043186322 cites W2081465456 @default.
• W2043186322 cites W2101888941 @default.
• W2043186322 cites W2106000003 @default.
• W2043186322 cites W2113056676 @default.
• W2043186322 cites W2125589729 @default.
• W2043186322 cites W2161467921 @default.
• W2043186322 cites W2163924299 @default.
• W2043186322 cites W4240811981 @default.
• W2043186322 cites W4255231289 @default.
• W2043186322 doi "https://doi.org/10.1016/j.surg.2008.07.028" @default.
• W2043186322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19040996" @default.
• W2043186322 hasPublicationYear "2008" @default.
• W2043186322 type Work @default.
• W2043186322 sameAs 2043186322 @default.
• W2043186322 citedByCount "21" @default.
• W2043186322 countsByYear W20431863222012 @default.
• W2043186322 countsByYear W20431863222013 @default.
• W2043186322 countsByYear W20431863222014 @default.
• W2043186322 countsByYear W20431863222015 @default.
• W2043186322 countsByYear W20431863222016 @default.
• W2043186322 countsByYear W20431863222017 @default.
• W2043186322 countsByYear W20431863222021 @default.
• W2043186322 countsByYear W20431863222023 @default.
• W2043186322 crossrefType "journal-article" @default.
• W2043186322 hasAuthorship W2043186322A5003360187 @default.
• W2043186322 hasAuthorship W2043186322A5006600520 @default.
• W2043186322 hasAuthorship W2043186322A5018065633 @default.
• W2043186322 hasAuthorship W2043186322A5018703548 @default.
• W2043186322 hasAuthorship W2043186322A5019885091 @default.
• W2043186322 hasAuthorship W2043186322A5040025890 @default.
• W2043186322 hasAuthorship W2043186322A5043079481 @default.
• W2043186322 hasAuthorship W2043186322A5056250241 @default.
• W2043186322 hasAuthorship W2043186322A5066779282 @default.
• W2043186322 hasAuthorship W2043186322A5076916905 @default.
• W2043186322 hasAuthorship W2043186322A5078377958 @default.
• W2043186322 hasAuthorship W2043186322A5080440906 @default.
• W2043186322 hasAuthorship W2043186322A5089773064 @default.
• W2043186322 hasConcept C104317684 @default.
• W2043186322 hasConcept C10515644 @default.
• W2043186322 hasConcept C121608353 @default.
• W2043186322 hasConcept C126322002 @default.
• W2043186322 hasConcept C143998085 @default.
• W2043186322 hasConcept C150194340 @default.
• W2043186322 hasConcept C203014093 @default.
• W2043186322 hasConcept C2779761222 @default.
• W2043186322 hasConcept C2781461381 @default.
• W2043186322 hasConcept C502942594 @default.
• W2043186322 hasConcept C51785407 @default.
• W2043186322 hasConcept C54355233 @default.
• W2043186322 hasConcept C57074206 @default.
• W2043186322 hasConcept C62478195 @default.
• W2043186322 hasConcept C71924100 @default.
• W2043186322 hasConcept C86803240 @default.
• W2043186322 hasConcept C95444343 @default.
• W2043186322 hasConceptScore W2043186322C104317684 @default.
• W2043186322 hasConceptScore W2043186322C10515644 @default.
• W2043186322 hasConceptScore W2043186322C121608353 @default.
• W2043186322 hasConceptScore W2043186322C126322002 @default.
• W2043186322 hasConceptScore W2043186322C143998085 @default.
• W2043186322 hasConceptScore W2043186322C150194340 @default.
• W2043186322 hasConceptScore W2043186322C203014093 @default.
• W2043186322 hasConceptScore W2043186322C2779761222 @default.
• W2043186322 hasConceptScore W2043186322C2781461381 @default.
• W2043186322 hasConceptScore W2043186322C502942594 @default.
• W2043186322 hasConceptScore W2043186322C51785407 @default.
• W2043186322 hasConceptScore W2043186322C54355233 @default.
• W2043186322 hasConceptScore W2043186322C57074206 @default.
• W2043186322 hasConceptScore W2043186322C62478195 @default.

• next